Biologics

China Approves ArkBio Aizhida For ADHD With Rapid Onset And All Day Symptom Control

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the...

 January 12, 2026 | News

M&G Leads $50 Million Series C In bit.bio To Scale Human Cell Programming

M&G Investments (M&G) announces that it has led a US$50 million Series C funding round for bit.bio, the Cambridge-based biotech company pionee...

 January 12, 2026 | News

AirNexis Secures Global Rights To Phase 2 COPD Asset AN01 In $200 Million Series A Backed By Frazier And OrbiMed

AirNexis acquires exclusive rights to develop AN01 outside of China from Haisco Pharmaceutical Group Company founded by Frazier Life Sciences, which led...

 January 12, 2026 | News

Biocytogen And Acepodia Advance Dual Payload Bispecific ADC Strategy Through Option Based Licensing Pact

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), announced that the companies have entered int...

 January 12, 2026 | News

One Genomics And CiRA Foundation Forge AI Powered Genome Engineering Alliance To Accelerate De Aging Science

AI-Focused Genomics Company Advancing De-Aging Science Collaborates with Leading iPS Cell Manufacturing and Research Foundation One Genomics, an...

 January 12, 2026 | News

Zai Lab Secures China Approval For AUGTYRO In NTRK Fusion Positive Solid Tumours

-Zai Lab Limited  announced that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sND...

 January 09, 2026 | News

ASGCT And Orphan Therapeutics Accelerator Launch CGTxchange To Revive Stalled Cell And Gene Therapies

First-of-its-kind venture to facilitate and catalyze development of deprioritized cell and gene therapies, supported by AI-enabled platform The American S...

 January 09, 2026 | News

Sidewinder Therapeutics Secures Multi Target ADC Licensing Agreement With Lonza

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform Sidewinder's pipeline...

 January 08, 2026 | News

Sichuan Kelun Biotech Secures NMPA IND Approval For SKB105 Antibody Drug Conjugate In Advanced Solid Tumours

 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) appli...

 January 07, 2026 | News

Amphix Bio Secures $12.5 Million Seed Financing To Advance Neurological Therapies

Amphix Bio announced the initial closing of a $12.5 million seed financing round to advance its lead therapeutic candidates toward human clinical trials an...

 January 02, 2026 | News

Nona Biosciences Expands Integrated Framework To Support Early Clinical Development And IITs

Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, announced the expansion o...

 January 02, 2026 | News

Harbour BioMed Partners With Lannacheng To Advance Next Generation Radionuclide Drug Conjugates

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunolo...

 January 02, 2026 | News

KLMBio Accelerates Global Expansion With High Value Human Tissue Based Bone Graft Portfolio

KLMBio, a manufacturer and exporter of human tissue-based medical devices, is accelerating its global business expansion by strengthening its high-value ti...

 January 01, 2026 | News

Mabwell Doses First Patient Globally In Phase II Trial Of IL 11 Antibody For Pathological Scarring

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of i...

 January 01, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close